Literature DB >> 18467370

Hypertension in rheumatoid arthritis.

V F Panoulas1, G S Metsios, A V Pace, H John, G J Treharne, M J Banks, G D Kitas.   

Abstract

RA associates with an increased burden of cardiovascular disease, which is at least partially attributed to classical risk factors such as hypertension (HT) and dyslipidaemia. HT is highly prevalent, and seems to be under-diagnosed and under-treated among patients with RA. In this review, we discuss the mechanisms that may lead to increased blood pressure in such patients, paying particular attention to commonly used drugs for the treatment of RA. We also suggest screening strategies and management algorithms for HT, specific to the RA population, although it is clear that these need to be formally assessed in prospective randomized controlled trials designed specifically for the purpose, which, unfortunately, are currently lacking.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18467370     DOI: 10.1093/rheumatology/ken159

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  93 in total

Review 1.  Rheumatoid cachexia and cardiovascular disease.

Authors:  Gregory D Summers; Giorgos S Metsios; Antonios Stavropoulos-Kalinoglou; George D Kitas
Journal:  Nat Rev Rheumatol       Date:  2010-07-20       Impact factor: 20.543

2.  Inflammation and hypertension in rheumatoid arthritis.

Authors:  Siriporn Manavathongchai; Aihua Bian; Young Hee Rho; Annette Oeser; Joseph F Solus; Tebeb Gebretsadik; Ayumi Shintani; C Michael Stein
Journal:  J Rheumatol       Date:  2013-09-01       Impact factor: 4.666

3.  Identifying common genetic variants in blood pressure due to polygenic pleiotropy with associated phenotypes.

Authors:  Ole A Andreassen; Linda K McEvoy; Wesley K Thompson; Yunpeng Wang; Sjur Reppe; Andrew J Schork; Verena Zuber; Elizabeth Barrett-Connor; Kaare Gautvik; Pål Aukrust; Tom H Karlsen; Srdjan Djurovic; Rahul S Desikan; Anders M Dale
Journal:  Hypertension       Date:  2014-01-06       Impact factor: 10.190

4.  Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.

Authors:  Inge A M van den Oever; Alper M van Sijl; Michael T Nurmohamed
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

5.  Impact of rheumatoid arthritis on receiving a diagnosis of hypertension among patients with regular primary care.

Authors:  Christie M Bartels; Heather Johnson; Katya Voelker; Carolyn Thorpe; Patrick McBride; Elizabeth A Jacobs; Nancy Pandhi; Maureen Smith
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-09       Impact factor: 4.794

Review 6.  Role of the Immune System in Hypertension.

Authors:  Bernardo Rodriguez-Iturbe; Hector Pons; Richard J Johnson
Journal:  Physiol Rev       Date:  2017-07-01       Impact factor: 37.312

7.  Asymmetric and symmetric dimethylarginine concentration as an indicator of cardiovascular diseases in rheumatoid arthritis patients: a systematic review and meta-analysis of case-control studies.

Authors:  Parisa Zafari; Ahmadreza Zarifian; Reza Alizadeh-Navaei; Mahdi Taghadosi; Alireza Rafiei; Zahra Samimi; Fatemeh Niksolat
Journal:  Clin Rheumatol       Date:  2019-08-03       Impact factor: 2.980

Review 8.  Cardiovascular comorbidity in rheumatic diseases.

Authors:  Michael T Nurmohamed; Maaike Heslinga; George D Kitas
Journal:  Nat Rev Rheumatol       Date:  2015-08-18       Impact factor: 20.543

9.  Vascular function and inflammation in rheumatoid arthritis: the role of physical activity.

Authors:  George S Metsios; Antonios Stavropoulos-Kalinoglou; Aamer Sandoo; Jet J C S Veldhuijzen van Zanten; Tracey E Toms; Holly John; George D Kitas
Journal:  Open Cardiovasc Med J       Date:  2010-02-23

10.  Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study.

Authors:  Tracey E Toms; Vasileios F Panoulas; Karen M J Douglas; Helen R Griffiths; George D Kitas
Journal:  Arthritis Res Ther       Date:  2008-12-17       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.